" class="no-js "lang="en-US"> Liam Taylor - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Liam Taylor

Liam Taylor

About Liam Taylor

Liam is a highly experienced senior executive with extensive knowledge of running commercial, operations, finance and innovation teams in the diagnostic, pharma and life science sector, both in the UK and US.

Related Story

Drug Development

 Axol Bioscience Introduces CiPA-validated Human Stem Cell-derived Ventricular Cardiomyocytes to Help Improve Drug Discovery | Pharmtech Focus

Axol Bioscience Introduces CiPA-validated Human Stem Cell-derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

June 8 2022

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science […]